β2m is a major histocompatibility complex (MHC)I component involved in several renal diseases. It is known to accumulate and form amyloids in dialysispatients, a condition known as dialysis-related amyloidosis. It may also play a role in the progression ofmultiple myeloma. Nanobodies against this11.9 kDa protein had been generated, and several had been shown tosuccessfully inhibit its aggregation. Based on our results with αGFP mutants, we chose to base β2mPEABS on the midnanomolar–affinity camel-derived nb24, whose bound structure to β2m had beensolved (Figure a). The gene discussed is B2M; the disease is plasma cell myeloma.